Public Advisory - Jamp-Atorvastatin 40 mg tablets recalled due to risk of latex contamination

OTTAWA, ON, Aug. 6, 2022 /CNW/ -

Summary

• Product: Jamp-Atorvastatin 40 mg tablets (lot MHC1403A, expiry 2023-09-30)
• Issue: Health product – Contamination
• What to do: Contact your pharmacy to confirm if you are taking medication from the affected lot. If you are, stop taking it and return it to your pharmacy for a replacement product and proper disposal.
• Who this is for: General public

Affected products

Product	DIN	Lot	Expiry
Jamp-Atorvastatin 40 mg tablets	02391074	MHC1403A	2023-09-30

Issue

Jamp Pharma Corporation is recalling one lot (MHC1403A) of Jamp-Atorvastatin 40 mg tablets due to possible contamination with latex pieces during manufacturing. A piece of latex was found in one tablet from the affected lot.

Atorvastatin is a prescription drug used to treat high cholesterol and other fats (such as triglycerides) in the blood, and to prevent cardiovascular disease such as heart attacks.

Ingesting latex can pose serious health risks for people with latex allergies, including severe allergic reactions (anaphylaxis). Symptoms of anaphylaxis include breathing difficulties, nausea, vomiting, and low blood pressure. Anaphylaxis can be life threatening. In addition, foreign material in the tablets may change their shape, which could make them difficult to swallow and lead to choking.

The Department is monitoring the company's recall and will inform Canadians if any new health risks are identified.

What you should do

• Contact your pharmacy to confirm if you are taking medication from the affected lot. If you are, stop taking it and return it to your pharmacy for a replacement product and proper disposal.
• Contact Jamp Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at [email protected], if you have questions about this recall.
• Report any health product adverse events or complaints to Health Canada.

Alert / recall type: Public Advisory
Category: Health products – Drugs
Published by: Health Canada

Également disponible en français

SOURCE Health Canada

Media Enquiries: Health Canada, 613-957-2983, [email protected]; Public Enquiries: 613-957-2991, 1-866 225-0709